abstract Objective: The aim was to formulate practice guidelines for the diagnosis and
treatment of hyperprolactinemia. Participants: The Task Force consisted of Endocrine …

Prevalence and incidence of prolactinomas are approximately 50 per 100,000 and 3–5 new
cases/100,000/year. The pathophysiological mechanism of hyperprolactinemia-induced …

Context: Data on the incidence of pituitary adenomas (PAs) are scant and outdated. A
population-based regional cohort with thorough case identification was used to evaluate the …

Pituitary adenomas are usually benign monoclonal tumours presenting either due to
hypersecretion of pituitary hormones, and/or due to local space occupying effects and …

Hyperprolactinemia is one of the most frequently diagnosed clinical disorders in routine
endocrine practice. Any process interfering with dopamine synthesis, its transport to the …

Context/Objective: Locally aggressive pituitary tumors (LAPT) and pituitary carcinomas
respond poorly to conventional therapy and cytotoxic drugs. Temozolomide (TMZ) is an oral …

Consensus guidelines recommend dopamine agonists (DAs) as the mainstay treatment for
prolactinomas. In most patients, DAs achieve tumor shrinkage and normoprolactinemia at …

Background Giant prolactinomas are an unusual subset of macroprolactinomas and are
more commonly found in men. The goal of this review is to propose a giant prolactinoma …

Objective Aggressive pituitary tumours may be difficult to treat. Temozolomide (TMZ) is an
alkylating cytostaticum. In a small number of cases, TMZ therapy has been reported to …

105 march 2010, vol. 68, no 3 rate similar to that of immunoglobulins. Depending on the
immunoassay used, macro prolactinaemia accounts for up to 25% of biochemically …